Cargando…

Impact of rewarming rate on interleukin-6 levels in patients with shockable cardiac arrest receiving targeted temperature management at 33 °C: the ISOCRATE pilot randomized controlled trial

PURPOSE: While targeted temperature management (TTM) has been recommended in patients with shockable cardiac arrest (CA) and suggested in patients with non-shockable rhythms, few data exist regarding the impact of the rewarming rate on systemic inflammation. We compared serum levels of the proinflam...

Descripción completa

Detalles Bibliográficos
Autores principales: Lascarrou, Jean-Baptiste, Guichard, Elie, Reignier, Jean, Le Gouge, Amélie, Pouplet, Caroline, Martin, Stéphanie, Lacherade, Jean-Claude, Colin, Gwenhael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8680374/
https://www.ncbi.nlm.nih.gov/pubmed/34920723
http://dx.doi.org/10.1186/s13054-021-03842-9
_version_ 1784616731943108608
author Lascarrou, Jean-Baptiste
Guichard, Elie
Reignier, Jean
Le Gouge, Amélie
Pouplet, Caroline
Martin, Stéphanie
Lacherade, Jean-Claude
Colin, Gwenhael
author_facet Lascarrou, Jean-Baptiste
Guichard, Elie
Reignier, Jean
Le Gouge, Amélie
Pouplet, Caroline
Martin, Stéphanie
Lacherade, Jean-Claude
Colin, Gwenhael
author_sort Lascarrou, Jean-Baptiste
collection PubMed
description PURPOSE: While targeted temperature management (TTM) has been recommended in patients with shockable cardiac arrest (CA) and suggested in patients with non-shockable rhythms, few data exist regarding the impact of the rewarming rate on systemic inflammation. We compared serum levels of the proinflammatory cytokine interleukin-6 (IL6) measured with two rewarming rates after TTM at 33 °C in patients with shockable out-of-hospital cardiac arrest (OHCA). METHODS: ISOCRATE was a single-center randomized controlled trial comparing rewarming at 0.50 °C/h versus 0.25 °C/h in patients coma after shockable OHCA in 2016–2020. The primary outcome was serum IL6 level 24–48 h after reaching 33 °C. Secondary outcomes included the day-90 Cerebral Performance Category (CPC) and the 48-h serum neurofilament light-chain (NF-L) level. RESULTS: We randomized 50 patients. The median IL6 area-under-the-curve was similar between the two groups (12,389 [7256–37,200] vs. 8859 [6825–18,088] pg/mL h; P = 0.55). No significant difference was noted in proportions of patients with favorable day-90 CPC scores (13/25 patients at 0.25 °C/h (52.0%; 95% CI 31.3–72.2%) and 13/25 patients at 0.50 °C/h (52.0%; 95% CI 31.3–72.2%; P = 0.99)). Median NF-L levels were not significantly different between the 0.25 °C/h and 0.50 °C/h groups (76.0 pg mL, [25.5–3074.0] vs. 192 pg mL, [33.6–4199.0]; P = 0.43; respectively). CONCLUSION: In our RCT, rewarming from 33 °C at 0.25 °C/h, compared to 0.50 °C/h, did not decrease the serum IL6 level after shockable CA. Further RCTs are needed to better define the optimal TTM strategy for patients with CA. Trial registration ClinicalTrials.gov, NCT02555254. Registered September 14, 2015. Take-Home Message: Rewarming at a rate of 0.25 °C/h, compared to 0.50 °C, did not result in lower serum IL6 levels after achievement of hypothermia at 33 °C in patients who remained comatose after shockable cardiac arrest. No associations were found between the slower rewarming rate and day-90 functional outcomes or mortality. 140-character Tweet: Rewarming at 0.25 °C versus 0.50 °C did not decrease serum IL6 levels after hypothermia at 33 °C in patients comatose after shockable cardiac arrest. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-021-03842-9.
format Online
Article
Text
id pubmed-8680374
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86803742021-12-20 Impact of rewarming rate on interleukin-6 levels in patients with shockable cardiac arrest receiving targeted temperature management at 33 °C: the ISOCRATE pilot randomized controlled trial Lascarrou, Jean-Baptiste Guichard, Elie Reignier, Jean Le Gouge, Amélie Pouplet, Caroline Martin, Stéphanie Lacherade, Jean-Claude Colin, Gwenhael Crit Care Research PURPOSE: While targeted temperature management (TTM) has been recommended in patients with shockable cardiac arrest (CA) and suggested in patients with non-shockable rhythms, few data exist regarding the impact of the rewarming rate on systemic inflammation. We compared serum levels of the proinflammatory cytokine interleukin-6 (IL6) measured with two rewarming rates after TTM at 33 °C in patients with shockable out-of-hospital cardiac arrest (OHCA). METHODS: ISOCRATE was a single-center randomized controlled trial comparing rewarming at 0.50 °C/h versus 0.25 °C/h in patients coma after shockable OHCA in 2016–2020. The primary outcome was serum IL6 level 24–48 h after reaching 33 °C. Secondary outcomes included the day-90 Cerebral Performance Category (CPC) and the 48-h serum neurofilament light-chain (NF-L) level. RESULTS: We randomized 50 patients. The median IL6 area-under-the-curve was similar between the two groups (12,389 [7256–37,200] vs. 8859 [6825–18,088] pg/mL h; P = 0.55). No significant difference was noted in proportions of patients with favorable day-90 CPC scores (13/25 patients at 0.25 °C/h (52.0%; 95% CI 31.3–72.2%) and 13/25 patients at 0.50 °C/h (52.0%; 95% CI 31.3–72.2%; P = 0.99)). Median NF-L levels were not significantly different between the 0.25 °C/h and 0.50 °C/h groups (76.0 pg mL, [25.5–3074.0] vs. 192 pg mL, [33.6–4199.0]; P = 0.43; respectively). CONCLUSION: In our RCT, rewarming from 33 °C at 0.25 °C/h, compared to 0.50 °C/h, did not decrease the serum IL6 level after shockable CA. Further RCTs are needed to better define the optimal TTM strategy for patients with CA. Trial registration ClinicalTrials.gov, NCT02555254. Registered September 14, 2015. Take-Home Message: Rewarming at a rate of 0.25 °C/h, compared to 0.50 °C, did not result in lower serum IL6 levels after achievement of hypothermia at 33 °C in patients who remained comatose after shockable cardiac arrest. No associations were found between the slower rewarming rate and day-90 functional outcomes or mortality. 140-character Tweet: Rewarming at 0.25 °C versus 0.50 °C did not decrease serum IL6 levels after hypothermia at 33 °C in patients comatose after shockable cardiac arrest. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-021-03842-9. BioMed Central 2021-12-17 /pmc/articles/PMC8680374/ /pubmed/34920723 http://dx.doi.org/10.1186/s13054-021-03842-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lascarrou, Jean-Baptiste
Guichard, Elie
Reignier, Jean
Le Gouge, Amélie
Pouplet, Caroline
Martin, Stéphanie
Lacherade, Jean-Claude
Colin, Gwenhael
Impact of rewarming rate on interleukin-6 levels in patients with shockable cardiac arrest receiving targeted temperature management at 33 °C: the ISOCRATE pilot randomized controlled trial
title Impact of rewarming rate on interleukin-6 levels in patients with shockable cardiac arrest receiving targeted temperature management at 33 °C: the ISOCRATE pilot randomized controlled trial
title_full Impact of rewarming rate on interleukin-6 levels in patients with shockable cardiac arrest receiving targeted temperature management at 33 °C: the ISOCRATE pilot randomized controlled trial
title_fullStr Impact of rewarming rate on interleukin-6 levels in patients with shockable cardiac arrest receiving targeted temperature management at 33 °C: the ISOCRATE pilot randomized controlled trial
title_full_unstemmed Impact of rewarming rate on interleukin-6 levels in patients with shockable cardiac arrest receiving targeted temperature management at 33 °C: the ISOCRATE pilot randomized controlled trial
title_short Impact of rewarming rate on interleukin-6 levels in patients with shockable cardiac arrest receiving targeted temperature management at 33 °C: the ISOCRATE pilot randomized controlled trial
title_sort impact of rewarming rate on interleukin-6 levels in patients with shockable cardiac arrest receiving targeted temperature management at 33 °c: the isocrate pilot randomized controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8680374/
https://www.ncbi.nlm.nih.gov/pubmed/34920723
http://dx.doi.org/10.1186/s13054-021-03842-9
work_keys_str_mv AT lascarroujeanbaptiste impactofrewarmingrateoninterleukin6levelsinpatientswithshockablecardiacarrestreceivingtargetedtemperaturemanagementat33ctheisocratepilotrandomizedcontrolledtrial
AT guichardelie impactofrewarmingrateoninterleukin6levelsinpatientswithshockablecardiacarrestreceivingtargetedtemperaturemanagementat33ctheisocratepilotrandomizedcontrolledtrial
AT reignierjean impactofrewarmingrateoninterleukin6levelsinpatientswithshockablecardiacarrestreceivingtargetedtemperaturemanagementat33ctheisocratepilotrandomizedcontrolledtrial
AT legougeamelie impactofrewarmingrateoninterleukin6levelsinpatientswithshockablecardiacarrestreceivingtargetedtemperaturemanagementat33ctheisocratepilotrandomizedcontrolledtrial
AT poupletcaroline impactofrewarmingrateoninterleukin6levelsinpatientswithshockablecardiacarrestreceivingtargetedtemperaturemanagementat33ctheisocratepilotrandomizedcontrolledtrial
AT martinstephanie impactofrewarmingrateoninterleukin6levelsinpatientswithshockablecardiacarrestreceivingtargetedtemperaturemanagementat33ctheisocratepilotrandomizedcontrolledtrial
AT lacheradejeanclaude impactofrewarmingrateoninterleukin6levelsinpatientswithshockablecardiacarrestreceivingtargetedtemperaturemanagementat33ctheisocratepilotrandomizedcontrolledtrial
AT colingwenhael impactofrewarmingrateoninterleukin6levelsinpatientswithshockablecardiacarrestreceivingtargetedtemperaturemanagementat33ctheisocratepilotrandomizedcontrolledtrial
AT impactofrewarmingrateoninterleukin6levelsinpatientswithshockablecardiacarrestreceivingtargetedtemperaturemanagementat33ctheisocratepilotrandomizedcontrolledtrial